# Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06532058** · PHASE2 · RECRUITING · sponsor: **Changzhou Qianhong Bio-pharma Co., Ltd.** · enrollment: 53 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

## Interventions

- **DRUG:** QHRD107 capsule，Venclexta and Azacitidine

## Key facts

- **NCT ID:** NCT06532058
- **Lead sponsor:** Changzhou Qianhong Bio-pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2025-02-10
- **Final completion:** 2025-05-10
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532058, "Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06532058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*